Quigley MD FRCP FACP MACG FRCPIbINTRODUCTIONProbiotics are widely used by patients with inflammatory bowel disease IBD and frequently recommended by their physicians usually as adjunctive therapy.1 How- ever despite their popularity and a widespread perception of safety the evidence base to support such extensive usage is thin.

This statement is not to deny a substan- tial theoretic basis for the use of therapies such as probiotics that modulate the gut microbiota in IBD.

The role of the gut microbiota in IBD has been extensively reviewed by Abigail R. Basson and colleagues' article Complementary and AlternativeDisclosure E.M.M.

